Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Mipomersen in Patients With Severe Hypercholesterolemia on a Maximally Tolerated Lipid-Lowering Regimen and Who Are Not on Apheresis.

Next Previous
Trial Profile

A Prospective Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Mipomersen in Patients With Severe Hypercholesterolemia on a Maximally Tolerated Lipid-Lowering Regimen and Who Are Not on Apheresis.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mipomersen (Primary)
  • Indications Abdominal aortic aneurysm; Carotid artery diseases; Hypercholesterolaemia; Hyperlipoproteinaemia type IIa; Myocardial infarction
  • Focus Registrational; Therapeutic Use
  • Sponsors Genzyme Corporation

Most Recent Events

  • 20 Nov 2013 Retrospective pooled tolerability analysis assessing incidence of cardiovascular events presented at the 86th Annual Scientific Sessions of the American Heart Association.
  • 06 Apr 2011 Efficacy and adverse events data presented at the 60th Annual Scientific Sessions of the American College of Cardiology (ACC-2011), according to a Genzyme and Isis Pharmaceuticals media release.
  • 06 Apr 2011 Secondary endpoint 'Lipoprotein-a-level' has been met.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top